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Background: Among the pro-inflammatory lipid mediators, platelet-activating factor (PAF) is a major primary and
secondary messenger that binds to the PAF-receptor (PAFR). Epidermal growth factor (EGF) is a polypeptide growth
factor that binds to the EGF-receptor (EGFR). Evidence suggests that both PAF and EGF play a significant role in
oncogenic transformation, tumor growth, neoangiogenesis and metastasis, including ovarian cancer. PAF has the
potential to transactivate EGFR in ovarian cancer cells. This study explores the mechanisms involved in EGF-induced
PAF production.
Methods: The effect of EGF on PAF production in ovarian cancer cells was observed using enzyme-linked
immunosorbent assay. The receptors transactivation and the role of cytosolic phospholipase A2 (cPLA2) in
modulating PAF production induced by EGF was assessed using pharmacological inhibitors, si-RNA knockdown,
targeted gene overexpression and immunocytochemistry. The signaling pathways invovled in PAF production
induced by EGF in ovarian cancer cells were assessed.
Results: We demonstrate that EGF increases the production of PAF in CAOV3 and SKOV3 ovarian cancer cell lines.
EGF induces the transactivation of PAFR, which can be blocked by an EGFR inhibitor. Inhibition of EGFR and/or
PAFR blocks PAF production in response to EGF. EGF-induced PAF production involves the phosphorylation of
extracellular-regulated protein kinase (ERK) and cytosolic phospholipase A2 (cPLA2). A cPLA2 inhibitor blocks
EGF-induced PAF production as well as si-cPLA2, while overexpression of cPLA2 increases PAF production.
Conclusions: These results indicate that EGF stimulates PAF production in ovarian cancer cells in a manner that
requires cPLA2. We have also determined that crosstalk can occur bidirectionally between EGFR and PAFR,
suggesting that EGF-induced PAF production could result in positive feedback that acts on the PAF-receptor to
promote ovarian cancer progression.
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Chronic inflammatory microenvironments have been
suggested as the major predisposing factor for ovarian
and other cancers [1]. Lipid mediators such as lysopho-
sphatidic acid (LPA) and prostaglandins (PGs), with their
specific receptors and pathways, have been shown to
play a critical role in cancer initiation and progression
[2-4]. Platelet activating factor (PAF, 1-O-alkyl-2-acetyl-
sn-glycero-3-phosphorylcholine) is also one of the most
potent lipid mediators involved in many different bio-
logical pathways in inflammatory diseases and cancers
[5,6]. There are two distinct pathways in which PAF can
be synthesized: the de novo pathway and the remodeling
pathway [7]. The de novo pathway is used to maintain
PAF levels during normal cellular function, while the re-
modeling pathway is activated by inflammatory agents
and is the primary source of PAF under pathological
conditions. The initiation of the remodeling pathway re-
quires membrane phospholipid hydrolysis by phospho-
lipase A2 (PLA2), which supplies lyso-PAF, a precursor
of PAF. Lyso-PAF acetyltransferase then converts lyso-
PAF into PAF and finally, PAF activates the PAF-receptor
(PAFR), a member of the superfamily of G protein-
coupled receptors [8,9]. These events are thought to play
an important role in the oncogenic transformation [10],
proliferation [11] and metastasis [12] of several types of
cancers, including ovarian cancers. However, PAF is rap-
idly degraded by PAF acetylhydrolases (PAF-AH), which
cleaves the acetyl group at the sn-2 position to reform
back to lyso-PAF [13]. Therefore, there maybe a possibility
that PAF acts as an autocrine growth factor to promote
ovarian cancer progression.
PLA2 is classified into three groups: group VI
calcium-independent PLA2s (iPLA2s), secretory PLA2s
(sPLA2s), and group IV cytosolic PLA2s (cPLA2) [14].
Group IVA cPLA2 is essential for producing PAF be-
cause PAF synthesis is significantly diminished in cal-
cium ionophore-stimulated macrophages derived from
group IVA cPLA2-deficient mice compared with those
from wild-type mice [15]. However, the role of cPLA2 in
growth factor-mediated PAF production in ovarian can-
cer cells has not been examined. The current study fo-
cuses on the role of cPLA2 in epidermal growth factor
(EGF)-stimulated PAF production in ovarian cancer
cells. Epidermal growth factor (EGF), a polypeptide
growth factor, binds to the EGF-receptor (EGFR), which
is a transmembrane protein tyrosine kinase. EGF is free
of sugar groups, has excellent chemical stability and is
highly prevalent in human blood. It also has been re-
ported that EGF stimulates proliferation of ovarian can-
cer cells and other types of carcinoma cells [16,17].
Our earlier study demonstrated that ovarian cancer cells
express high levels of PAFR as well as that PAF can stimu-
late transactivation of the EGFR in ovarian cancer cells[18]. PAF can activate matrix metalloproteases, which
cleave pro-EGF from the membrane to release active li-
gands. Intracellular signaling molecules, such as phospho-
lipase C and protein kinase A, have also been suggested as
mediators of PAF-induced transactivation of receptor
tyrosine kinase. Conversely, some growth factors and cyto-
kines can activate PAF production, resulting in transacti-
vation of the PAF receptor [19]. However, it has not yet
been tested whether reverse crosstalk occurs and whether
EGF can stimulate activation of PAFR.
In this study, we used CAOV3 and SKOV3 adenocar-
cinoma cells, two well-characterized human ovarian can-
cer cell lines, as models to examine the mechanisms
involved in EGF-induced PAF production. Stimulation of
cells with EGF increases PAF levels in the medium. This
response can be inhibited by either EGFR or PAFR in-
hibition. EGF recruits cPLA2 by activating the ERK sig-
naling pathway and overexpression of cPLA2 increases
PAF production, while inhibition of cPLA2 blocks EGF-
induced PAF production. These results show that EGF
activates cPLA2, that cPLA2 is involved in the produc-
tion of PAF and that bidirectional crosstalk can occur
between the EGF and the PAF receptors.
Materials and methods
Cell culture and chemical reagents
The ovarian cancer cell lines CAOV3 and SKOV3
(obtained from the Cell Bank of the Chinese Academy of
Science, Shanghai, China) were maintained at 37°C in a hu-
midified 5% CO2 atmosphere in RPMI-1640 medium with
10% fetal calf serum (Gibco, Invitrogen, Carlsbad, CA),
100 IU/ml penicillin G, and 100 mg/ml streptomycin sul-
fate (Sigma-Aldrich, St. Louis, MO). Cells were serum
starved by incubation in serum-free medium for 12–24
hours before the start of the experiments. Lipofectamine
2000 Transfection Reagent and Opti-MEM-1 Medium
(Invitrogen, Carlsbad, CA) were used for plasmid and
siRNA transfection. The vector encoding cPLA2 and
cPLA2-targeted siRNA were synthesized by Shanghai
GenePharma Co. AG1478 (EGFR inhibitor) [20] and
WEB2086 (PAFR inhibitor) were purchased from Sigma-
Aldrich (St Louis, MO). PD98059 (ERK inhibitor) and
LY294002 (PI3K inhibitor) were obtained from Cell Signal-
ing Technology (Boston, MA). Rabbit polyclonal antibodies
that were used in this study were directed against phospho/
total-EGFR, phospho/total-PLCβ, phospho/total-cPLA2,
phospho/total-Akt, and phospho/total-ERK. All the anti-
bodies were purchased from Cell Signaling Technology Co.
The mouse monoclonal antibodies that were used in this
study were directed against actin (Sigma, Missouri, USA).
Western blot analysis
Cellular extracts were prepared in modified radioimmu-
noprecipitation assay (RIPA) buffer (50 mM Tris–HCl
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1 mM EDTA, 1 mM PMSF, protease inhibitor cocktail).
Protein concentrations of cellular extracts were measured
using a Bio-Rad protein assay kit. Then, cellular extracts
were subjected to SDS-PAGE. Proteins were transferred
to PVDF membranes. After blocking for 1 h at room
temperature in 5% BSA, blots were probed with the pri-
mary antibody at a 1:1000 dilution and incubated over-
night at 4°C. Subsequently, blots were washed three times
and incubated for 1 h at room temperature with a 1:10000
dilution of secondary peroxidase-conjugated antibodies.
Following three washes, immunoreactive bands were de-
tected using electrochemiluminescence (ECL).
Transfection with cPLA2 overexpression vector
Cells were seeded and grown to approximately 40% con-
fluence. Cells were then transfected with the CMV-
MCS-EGFP-SV40-Neomycin-cPLA2 expression vector
using Lipofectamine2000. Briefly, cells were transfected
for 48 hours with 1 μg of DNA and were then serum-
starved for 12 hours before experimentation.
Incubation with small interference RNA for cPLA2
Cells were seeded and grown to approximately 40% conflu-
ence. Cells were incubated with 50 nM siRNA for cPLA2
or non-target siRNA, using Lipofectamine 2000 for
48 hours, based on the manufacture’s protocol. Cells were
then serum starved for 12 hours before experimentation.
PAF assay
Aliquots of the supernatant from stimulated ovarian
cancer cells were collected and the PAF concentrations
were measured using a specific enzyme immunoassay kit
(Cayman Chemical, Ann Arbor, MI). The assay was per-
formed according to the manufacturer’s instructions.
PAF production was evaluated in duplicates, and the
concentrations were determined from a standard curve
of PAF. The sensitivity of the assay allowed for the de-
tection of up to 15 pg/ml. When necessary, the samples
were diluted in the assay buffer.
Immunocytochemistry
After the drug treatment, the cells were fixed with 100%
methanol for 6 min at −20°C, then washed with PBS
and left at 4°C until use. Cells were permeabilized by in-
cubation in PBS containing 0.3% Triton X-100 and 5%
goat serum for 30 min. A polyclonal antibody against
phospho-cPLA2 was used at a 1:100 dilution, and a sec-
ondary antibody FITC-conjugated goat anti-rabbit
(Invitrogen, Carlsbad, CA), was used at a 1:200 dilution.
The first antibody was incubated overnight at 4°C and
the second antibody for 2 hours at RT. Images were
captured with an Olympus DP 71 camera (Tokyo,
Japan). The magnification level was 400 ×.Statistical analysis
All experiments were performed at least three times.
The data are expressed as the mean ± SD. Wherever ap-
propriate, the data were also subjected to unpaired, two-
tailed Student’s t-tests. Differences were considered sig-
nificant when P < 0.05.
Results
Effects of EGF on PAF production in ovarian cancer cells
As shown in Figure 1, in CAOV3 ovarian cancer cell lines,
extracellular EGF caused a significant rise in the PAF
released from 0.5 ng/ml to 100 ng/ml; while in SKOV3
ovarian cancer cell lines, ext racellular EGF caused a signifi-
cant rise in the PAF release from 1 ng/ml to 100 ng/ml.
The maximum effect was reached with 25 ng/ml of EGF
(1.952 ± 0.9-fold) in CAOV3 (Figure 1A) cells and 10 ng/ml
EGF (1.414 ± 0.3-fold) in SKOV3 cells (Figure 1B). Both in
CAOV3 and SKOV3 cells, PAF production increased after
20 min of stimulation with EGF (10 ng/ml) and continued
to rise to a maximum after 1 h. Longer stimulation of EGF
(24 h) caused no significant additional increase in PAF re-
lease over that obtained at 1 h (Figure 1C and D). Together,
our data indicated that EGF stimulates PAF production in
two human ovarian cancer cell lines.
EGFR transactivates PAFR followed by EGF stimulation
Our previous data has shown that PAF can transactivate
the EGFR, and EGF and PAF are shown to activate many
of the same intracellular signaling pathways. Conversely,
to test whether a growth factor might transactivate
PAFR, we first stimulated CAOV3 and SKOV3 cells with
10 ng/ml of EGF for varying times (5 min to 120 min) to
observe the change in phosphorylation of EGFR and
phosphoinositide-specific phospholipase C-β (PLCβ).
PLCβ has been shown to lie downstream of the activated
PAFR and, therefore, the phosphorylation of PLCβ indi-
cates the PAFR activation [21-23]. As shown in Figure 2A
and B, stimulation with EGF (10 ng/ml) evoked EGFR
and PLCβ phosphorylation in a time-dependent manner
in CAOV3 and SKOV3 cells. Phosphorylation of EGFR
reached maximum activation at 5 min, followed by a
subsequent reduction to the baseline by 120 min. Mean-
while, the phosphorylation of PLCβ increased gradually
and reached a maximum activation at 120 min. We also
observed that in both the cells, the phosphorylation of
PLCβ was somewhat slower than the phosphorylation of
EGFR after stimulation with EGF, suggesting the mech-
anism of EGF-induced transactivation of PAFR.
We next investigated whether EGF-induced PAFR trans-
activation is EGFR-dependent. Serum-starved CAOV3 and
SKOV3 cells were treated with AG1478 (10 μM), an EGFR-
specific tyrosine kinase inhibitor, for 1 h before exposing
them to EGF (10 ng/ml) for 10 min. As shown in Figure 2C
and D, AG1478 inhibited the phosphorylation of EGFR and
Figure 1 Effects of epidermal growth factor (EGF) on platelet-activating factor (PAF) production in ovarian cancer cells. (A and B) Release of
PAF in response to increasing concentrations of EGF for 1 h. CAOV3 and SKOV3 cells were serum starved and then stimulated with indicated
concentrations (0.5 to 100 ng/ml) of EGF. (C and D) Time course of PAF increase in response to 10 ng/ml EGF. CAOV3 and SKOV3 cells were treated with
EGF for the indicated time (20 min to 24 h) while measuring PAF production. Bars represent the average of triplicates ± S.D.; “*” (p < 0.05) and “**” (p < 0.01)
indicate a statistically significant difference compared to the untreated control.
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results suggest that EGF can induce PAFR transactivation
and that PAFR transactivation is EGFR-dependent.
Effects of EGFR and PAFR inhibition on PAF production in
ovarian cancer cells
EGF-induced PAF production is presumably mediated
through EGFR-mediated activation of phospholipases. To
address the potential for crosstalk between EGFR and PAFR,
we tested whether EGFR and PAFR activation correlated
with increased PAF production. AG1478 (an EGFR-specific
tyrosine kinase inhibitor) and WEB2086 (a small molecular
inhibitor of PAFR) were used to block EGFR and PAFR
activation. CAOV3 and SKOV3 cells were pretreated with
10 μM of AG1478 or 50 μM of WEB2086 or a combination
of AG1478 and WEB2086 for 30 min. The cells were then
incubated with 10 ng/ml of EGF for 30 min, and PAF
production was measured using an ELISA assay. As shown
in Figure 3, AG1478 and WEB2086 significantly reduced
the EGF-induced increase in PAF levels in both ovarian
cancer cell lines. Additive PAF-production-inhibiting effects
were observed on the combined inhibition of both recep-
tors. Taken together, these results suggest that both EGFR
and PAFR are involved in EGF-induced PAF production.
Akt and ERK lie downstream of activated EGFR and PAFR,
and ERK is required for activation of cPLA2
We next investigated the signaling pathway downstream of
activated EGFR and PAFR in ovarian cancer cells toelucidate the mechanisms involved in EGF-induced PAF
production. Western blots using an antibody that specific-
ally recognized the phosphorylated forms of Akt and ERK
were used. As shown in Figure 4A and B, exposure to
10 ng/ml of EGF caused the rapid phosphorylation of Akt
and ERK in CAOV3 and SKOV3 cells. We then investi-
gated the effects of the EGFR inhibitor, AG1478, and the
PAFR inhibitor, WEB2086, to determine whether both
EGFR and PAFR were involved in Akt and ERK activation
using EGF. Preincubation with 10 μM of AG1478 and/or
50 μM of WEB2086 for 1 h totally prevented the activa-
tion of Akt and ERK, following stimulation using 10 ng/ml
of EGF for 10 min. These data suggest that EGF activates
downstream Akt and ERK signaling via EGFR and PAFR.
To further analyze the mechanisms of EGF-induced PAF
production, we examined what is required for activation of
cPLA2 among the activated downstream signaling path-
ways. As shown in Figure 4C and D, exposure to EGF
caused the significant phosphorylation of cPLA2 in CAOV3
and SKOV3 cells. The activation of cPLA2 was treated
using 10 ng/ml of EGF for 10 min. The phosphorylation of
cPLA2, stimulated by EGF, could be blocked using by
10 μM of PD98059 (an ERK inhibitor), while no inhibition
was observed with LY294002 (10 μM), which binds to the
site of PI3K, thereby preventing the activation of target
enzymes, such as Akt. Furthermore, the staining intensity
of phosphorylated of cPLA2, following 10 min of 10 ng/ml
EGF treatment, was much higher in CAOV3 and SKOV3
cells than in control cells, and when cells were pretreated
Figure 3 Effects of an EGFR inhibitor and PAFR inhibitor on EGF-induced PAF production. CAOV3 (A) and SKOV3 (B) cells were serum
starved and then pretreated with 10 μM AG1478 or 50 μM WEB2086 or a combination of AG1478 and WEB2086 for 30 min. Cells were then
stimulated with 10 ng/ml EGF for 30 min. Medium was harvested, and the amount of PAF was measured. In A and B, bars represent the average
of triplicates ± S.D.; “*” (p < 0.05) and “**” (p < 0.01) indicate a statistically significant difference compared to the untreated control.
Figure 2 PAFR-coupled PLCβ phosphorylation induced by EGF in ovarian cancer cells. CAOV3 (A) and SKOV3 (B) cells were treated with a
constant dose (10 ng/ml) of EGF for different time intervals, as indicated. Total protein was extracted and analyzed for phospho-EGFR/total-EGFR and
phospho-PLCβ/total-PLCβ and was examined by immunoblot analysis. β-actin was used as an internal control. CAOV3 (C) and SKOV3 (D) cells were
pretreated with 10 μM AG1478 for 1 h before exposure to 10 ng/ml EGF for 10 min. Total protein was extracted and analyzed for phospho-EGFR/total-
EGFR and phospho-PLCβ/total-PLCβ and was examined by immunoblot analysis. β-actin was used as the internal control. Bars represent the average
of the triplicates ± S.D.; “*” (p < 0.05) and “**” (p < 0.01) indicate a statistically significant difference compared to the untreated control.
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Figure 4 Akt and ERK phosphorylation induced by EGF in ovarian cancer cells and ERK is required for activation of cPLA2. CAOV3 (A) and
SKOV3 (B) cells were pretreated with AG1478 (10 μM) and/or WEB2086 (50 μM) for 1 h before exposure to EGF (10 ng/ml) for 10 min. Total protein was
extracted and analyzed for phospho-Akt/total-Akt and phospho-ERK/total-ERK and was examined by immunoblot analysis. β-actin was used as a loading
control. CAOV3 (C) and SKOV3 (D) cells were pretreated with the ERK inhibitor PD98059 (10 μM) and the Akt inhibitor LY294002 (10 μM) before exposure
to EGF (10 ng/ml) for 10 min. Total protein was extracted and analyzed, and phospho-cPLA2/total-cPLA2 was examined by immunoblot analysis. β-actin
was used as a loading control. For the immunofluorescence staining of phosphorylated cPLA2 in CAOV3 (E) and SKOV3 (F) cells, after 10 min of incubation
without any drug or with 10 ng/ml of EGF or with 10 ng/ml of EGF plus 10 μM of PD98059, cells were labeled with polyclonal antibody to phosphorylated
cPLA2 overnight, and then cells were incubated with fluoresent secondary antibody to phospho- cPLA2 for 1 h and stained with DAPI for 10 min.
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phosphorylated of cPLA2 was reduced (Figure 4E and F).
These data indicate that ERK is required for the phosphor-
ylation of cPLA2 in ovarian cancer cells.
Effects of cPLA2 on EGF-induced PAF production
To determine whether cPLA2 is essential for producing
PAF stimulated by EGF in ovarian cancer cells, we first
tested for the effects of arachidonyl trifluoromethyl ketone
(AACOCF3), a small-molecular inhibitor of cPLA2 [24,25]
on PAF production. As shown in Figure 5A and B, CAOV3
and SKOV3 cells were pretreated with AACOCF3 (10 μM)for 30 min before exposing the cells to EGF (10 ng/ml) for
30 min. cPLA2 inhibition by AACOCF3 restained PAF
production induced by EGF in both cells. To further
analyze the effect of cPLA2 inhibition on PAF production,
we suppressed cPLA2, through RNA interference in
CAOV3 and SKOV3 cells before the stimulation with EGF.
Our data suggest that cPLA2-targeted siRNA was able to
effectively silence the expression and that the suppression
of cPLA2 led to the inhibition of PAF production when cells
were exposed to EGF compared to EGF alone (Figure 5C
and D). Furthermore, we overexpressed cPLA2 in CAOV3
and SKOV3 cells using an expression vector encoding
Figure 5 Role of cytosolic phospholipase A2 (cPLA2) in EGF-induced PAF production in ovarian cancer cells. CAOV3 (A) and SKOV3
(B) cells were serum starved and then pretreated with the cPLA2 inhibitor AACOCF3 (10 μM) for 30 min. Cells were then stimulated with
10 ng/ml EGF for 30 min. Medium was harvested, and the amount of PAF was measured. (C and D) CAOV3 and SKOV3 cells were transfected
with a negative-control (NC) or cPLA2-targeted siRNAs. Following 48 h of transfection, cells were treated with EGF (10 ng/ml) for 30 min. Medium
was harvested, and the amount of PAF was measured. (E and F) CAOV3 and SKOV3 cells were transfected with the cPLA2 overexpression vector
for 48 h. Cells were then treated with EGF (10 ng/ml) for 30 min. Medium was harvested, and the amount of PAF was measured. Bars represent
the average of triplicates ± S.D.; “*” (p < 0.05) and “**” (p < 0.01) indicate a statistically significant difference compared to the untreated control.
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induced PAF production. As shown in Figure 5E and F, the
vector encoding cPLA2 significantly increased the expres-
sion in CAOV3 and SKOV3 cells, and the overexpression
of cPLA2 enhanced the PAF production over control cells.
However, EGF did not further increase the PAF production
in cells overexpressing cPLA2, which may reflect a limit to
the amount of PAF that can be produced. Together, our
data suggest a role for cPLA2 in EGF-induced production
in ovarian cancer cells.Discussion
The results of this study demonstrate that EGF stimu-
lates the release of PAF from human ovarian cancer cells
by acting on the EGF-receptor and transactivating the
PAF-receptor. Stimulation of EGFR and PAFR led to the
activation of Akt and ERK, but only the phosphorylation
of ERK could stimulate the cPLA2 enzyme, resulting in
the production of PAF (Figure 6).
This is the first study to examine the role of EGF, a mito-
genic agonist that binds to EGFR, a tyrosine kinase receptor,
Figure 6 Proposed cascade of the mechanisms involved in PAF production by extracellular EGF in ovarian cancer cells. Extracellular EGF
binds to the EGF-receptor (EGFR) and transactivates the PAFR. Activation of EGFR and PAFR stimulates the phosphorylation of Akt and ERK. Only
the ERK pathway induces the phosphorylation of cPLA2, the latter increases the production of PAF.
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of EGFR is common in cancers, including 35-70% of ovarian
cancers [26-28]. The release of PAF stimulated by EGF can
be blocked by AG1478, an inhibitor of EGFR, as expected.
Interestingly, WEB2086, an inhibitor of PAFR, also blocks
EGF-stimulated PAF production, suggesting that crosstalk
between the receptors (EGFR and PAFR) is required.
We have previously observed that the tyrosine phospho-
activation of protein targets, including EGFR, were
significantly increased after PAF treatment, and that
phosphorylation was blocked or inhibited by the PAFR
antagonist Ginkgolide B using phospho-antibody micro-
array technologies [18]. Phosphoinositide-specific phospho-
lipase C (PLC) plays a significant role in transmembrane
signaling and the subfamily of PLCβ are activated by the G-
proteins. Our previous data revealed that PAF can activate
PLCβ-dependent PKC and Ca2+ pathways via PAFR to pro-
mote ovarian cancer progression. In this study, we demon-
strate that EGF stimulates the phosphorylation of PLCβ,
which can be blocked by the EGFR inhibitor AG1478, sug-
gesting that the crosstalk occurs bidirectionally between
EGFR and PAFR in ovarian cancer cell lines.
PAFR expression is elevated in non-mucinous types of
ovarian cancer tissues and cells, suggesting its role in the
pathogenesis and progression of ovarian cancer. PAF, the
sole ligand of PAFR, is secreted by many different cell types,
including endothelial, stromal and inflammatory cells, as
well as many different tumor cells [29-31], thus indicating
an important role of PAF/PAFR signaling in ovarian cancer
progression. In addition, it has been showen that PAF/
PAFR significantly promotes ovarian cancer proliferation
and invasion [32,33]. The mechanisms, however, in whichPAF accumulates in the extracellular space to activate PAFR
is still unknown. PAF may be produced within the cell
membrane and then exported out of the cell, or it may be
synthetized extracellularly. In the present study, we ob-
served that EGF treatment led to an increased production
of PAF. As we have demonstrated that PAF-induced ovar-
ian cancer cell proliferation and invasion is dependent on
PAFR, it can be assumed that PAF is an autocrine growth
factor for ovarian cancer.
The current study demonstrates that EGF stimulates
the phosphorylation of Akt and ERK, which can be
blocked by either AG1478, an inhibitor of EGFR, or
WEB2086, an inhibitor of PAFR. This suggests that
EGFR and PAFR, stimulated by EGF, can potentially ac-
tivate common downstream intracellular signaling path-
ways. ERK inhibition with PD98059 completely abolishes
the phosphorylation of cPLA2, while the antagonist of
Akt had no effect on the activation of cPLA2, suggesting
that the phosphorylation of cPLA2 induced by EGF is
ERK-dependent. In rat articular chondrocytes, the phos-
phorylation of ERK and p38 MAPKs activated cPLA2
and increased PGE2 production, which is another type
of lipid mediator, similar to PAF [34]. Phosphorylated
ERK in dorsal root ganglion neurons, caused by spinal
cord injury, can induce increased levels of PGE2 [35].
Whether EGF could affect the expression of cPLA2 and
whether cPLA2 could affect the production of PAF re-
quires further research in ovarian cancer cells.
cPLA2 can be activated by small GTPases, receptor tyro-
sine kinases, and phosphatidylinositides [36,37]. In this
study, we have shown that the phosphorylation of cPLA2 is
stimulated by EGF in ovarian cancer cells. Further, we have
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tion, as both of the specific cPLA2 inhibitors, AACOCF3
and cPLA2-targeted siRNA, block PAF production, while
exogenously added cPLA2 promotes PAF production. The
role of cPLA2 in smooth muscle cell spreading and/or mi-
gration has also been well documented [38]. The results
concerning the role of cPLA2 in EGF-induced PAF produc-
tion, along with the convergence of signaling molecules on
cPLA2, suggest that cPLA2 may be a potential therapeutic
target in ovarian cancer.
Conclusions
Taken together, our results identify mechanisms leading
to PAF production and reveal a novel autocrine loop in
ovarian cancer cells. Extracellular EGF could stimulate
the release of PAF, and this signaling pathway depends
on the transactivation between EGFR and PAFR. This
requires the phosphorylation of ERK and cPLA2, though
the activation of Akt is not involved in this pathway.
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